Literature DB >> 19799587

Infliximab in serpiginous choroiditis.

Pascal Seve, Emeline Mennesson, Jean-Daniel Grange, Christiane Broussolle, Laurent Kodjikian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19799587     DOI： 10.1111/j.1755-3768.2009.01738.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  7 in total

1.  Different outcomes of serpiginous choroiditis with or without ocular and systemic treatment.

Authors:  Zhong-Shan Chen; Qin Ding; Yan-Ping Song; Li Zhu; Zhi-Jian Huang; Ming Yan
Journal:  Int J Ophthalmol       Date:  2012-08-18       Impact factor: 1.779

Review 2.  Serpiginous choroiditis and infectious multifocal serpiginoid choroiditis.

Authors:  Hossein Nazari Khanamiri; Narsing A Rao
Journal:  Surv Ophthalmol       Date:  2013-03-27       Impact factor: 6.048

Review 3.  Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.

Authors:  Ioannis Papasavvas; Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-24

Review 4.  Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.

Authors:  Sirichai Pasadhika; James T Rosenbaum
Journal:  Biologics       Date:  2014-02-15

Review 5.  Enigma of serpiginous choroiditis.

Authors:  Parthopratim Dutta Majumder; Jyotirmay Biswas; Amod Gupta
Journal:  Indian J Ophthalmol       Date:  2019-03       Impact factor: 1.848

Review 6.  Tuberculosis-related serpiginous choroiditis: aggressive therapy with dual concomitant combination of multiple anti-tubercular and multiple immunosuppressive agents is needed to halt the progression of the disease.

Authors:  Ioannis Papasavvas; Bruno Jeannin; Carl P Herbort
Journal:  J Ophthalmic Inflamm Infect       Date:  2022-02-08

Review 7.  Diagnosis and Treatment of Primary Inflammatory Choriocapillaropathies (PICCPs): A Comprehensive Overview.

Authors:  Ioannis Papasavvas; Carl P Herbort
Journal:  Medicina (Kaunas)       Date:  2022-01-21       Impact factor: 2.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.